Paper Details

  1. Home
  2. Paper Details

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2).

Author: , BlonskiJerzy Z, CalbeckaMalgorzata, CeglarekBernadetta, DmoszynskaAnna, Dwilewicz-TrojaczekJadwiga, Gora-TyborJoanna, JamroziakKrzysztof, KasznickiMarek, KloczkoJanusz, KonopkaLech, KowalMalgorzata, KuliczkowskiKazimierz, RobakTadeusz, SkotnickiAleksander B, Stella-HolowieckaBeata, SulekKazimierz, TomaszewskaAgnieszka, WarzochaKrzysztof, ZawilskaKrystyna

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This prospective randomized trial compared the efficacy and toxicity of cladribine (2-CdA) alone to 2-CdA combined with cyclophosphamide (CC) or cyclophosphamide and mitoxantrone (CMC) in treating untreated progressive chronic lymphocytic leukemia (CLL).
Paper Details　
Original Abstract of the Article :
In this prospective randomized trial, we compared the efficacy and toxicity of cladribine (2-CdA) alone to 2-CdA combined with cyclophosphamide (CC) or cyclophosphamide and mitoxantrone (CMC) in untreated progressive chronic lymphocytic leukemia (CLL). Study end points were complete response (CR), o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1182/blood-2005-12-4828

データ提供：米国国立医学図書館（NLM）

Cladribine: A Promising Treatment for Chronic Lymphocytic Leukemia

The quest for effective treatments for chronic lymphocytic leukemia (CLL) continues. This study compares the efficacy and toxicity of cladribine (2-CdA) alone to various combinations of 2-CdA with other chemotherapy agents, such as cyclophosphamide and mitoxantrone. The research aims to evaluate the optimal treatment approach for patients with progressive CLL.

Cladribine Combination Therapy: A Powerful Alliance

This study underscores the potential of cladribine, especially in combination with other chemotherapy agents, for treating progressive chronic lymphocytic leukemia. The findings suggest that while cladribine alone can be effective, combining it with other agents, particularly mitoxantrone, may lead to higher response rates and potentially improved disease control.

Navigating the Shifting Sands of Leukemia Treatment

This research is like a desert explorer charting a new course for navigating the challenging landscape of leukemia treatment. The study offers valuable insights into the potential benefits and risks of various cladribine-based therapies, providing valuable information for healthcare professionals and patients seeking effective treatment options.

Dr.Camel's Conclusion

This study, like a well-traveled caravan carrying vital supplies, offers a promising path toward treating chronic lymphocytic leukemia. The research highlights the potential benefits of cladribine, especially in combination with other chemotherapy agents, offering hope for patients seeking effective and potentially life-saving treatment options.

Date :
  1. Date Completed 2006-08-22
  2. Date Revised 2021-02-06
Further Info :

Pubmed ID

16551966

DOI: Digital Object Identifier

10.1182/blood-2005-12-4828

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.